Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.29 – $1.53
Volume2,405
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.86M
Price / earnings
—
Price / book
1.9×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.65×
Profitability
Earnings per share
-$1.10
Return on assets
-124.12%
Return on equity
-157.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.7×
Quick ratio
4.7×
Cash ratio
3.15×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PULM, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$3K
$366K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$3K
$366K
Selling, general and administrative
$1.04M
$1.29M
$911K
$858K
$1.53M
$1.83M
$1.95M
$2.21M
Research and development
$2K
$3K
-$3K
$8K
$14K
$19K
$6K
$814K
Total operating expenses
$1.05M
$1.29M
$908K
$866K
$1.55M
$1.85M
$4.57M
$3.02M
Operating income
-$1.05M
-$1.29M
-$908K
-$866K
-$1.55M
-$1.85M
-$4.57M
-$2.66M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$1.04M
-$1.17M
-$928K
-$877K
-$1.55M
-$1.81M
-$1.99M
-$2.59M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.04M
-$1.17M
-$928K
-$877K
-$1.55M
-$1.81M
-$1.99M
-$2.59M
Net income attributable to common shareholders
-$1.05M
-$1.17M
-$928K
-$877K
-$1.55M
-$1.81M
-$1.99M
-$2.59M
EBITDA
-$1.05M
-$1.29M
-$908K
-$866K
-$1.55M
-$1.85M
-$1.95M
-$2.66M
Basic earnings per share
-$0.29
-$0.32
-$0.25
-$0.24
-$0.42
-$0.50
-$0.54
-$0.71
Diluted earnings per share
-$0.29
-$0.32
-$0.25
-$0.24
-$0.42
-$0.50
-$0.54
-$0.71
Recent news
Company coverage with links to the original publishers.
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The investigations concern whether shareholders are receiving fair consideration in these transactions, with concerns that insiders may benefit disproportionately and deal terms may prevent superior competing offers.
Eos SENOLYTIX presented preclinical data for its lead candidate PTC-2105, a mitochondrial-targeted geropeptide showing improvements in body composition with lean mass gains and fat reduction without the muscle loss associated with GLP-1 therapies. The company also announced a merger agreement with Pulmatrix, Inc., expected to close in Q3 2026 under the new ticker symbol MTXL. Preclinical studies demonstrated extended survival in aged mice and prevention of age-related decline.
Pulmatrix, Inc. (PULM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.76% and 24.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.